Clinical trials
Neuroendocrine Neoplasm clinical trials
Below are recruiting neuroendocrine neoplasm clinical trials, each written for real people, not researchers. We’re tracking 65 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03206060RecruitingPhase 2
Lu-177 DOTATATE for hard-to-remove pheochromocytoma or paraganglioma
This trial studies Lu-177 DOTATATE (Lutathera), a targeted radiation medicine, for tumors that cannot be safely removed with surgery. It aims to shrink or control pheochromocytoma/paraganglioma that is showing recent growth and has a specific target signal on a special PET scan.
Bethesda, MarylandAges 18–100 - NCT06276309Recruiting
Protein study of cervical neuroendocrine tumors
This study looks at the proteins in cervical neuroendocrine tumors to understand how they behave and how they affect long-term outcomes. It aims to find new markers that could help predict prognosis and guide treatment.
Fuzhou, FujianAges Any age - NCT06337760Recruiting
Young Adults with Digestive and Neuroendocrine Cancers
This trial studies treatments for young adults (ages 18-39) with cancers of the digestive system or neuroendocrine tumors. It aims to find better ways to help this age group, no matter the cancer stage or grade.
MilanAges 18–39 - NCT06577987RecruitingPhase 1
Study of CID-078 for advanced solid tumors
This trial tests an experimental drug called CID-078 for people with advanced solid tumors that have stopped responding to other treatments. It aims to find the right dose and see if the drug can shrink tumors.
Sarasota, FloridaAges 12 years+ - NCT06855095RecruitingPhase 2/Phase 3
PRRT with long-acting hormone therapy for neuroendocrine tumors
This trial tests combining peptide receptor radionuclide therapy (PRRT) with long-acting somatostatin analogues to see how much radiation reaches the tumor. It is for people with neuroendocrine tumors who meet the standard criteria for PRRT.
AmsterdamAges 18 years+ - NCT04949282Recruiting
Lutetium-177 treatment for advanced somatostatin-positive tumors
This study looks at outcomes for adults with tumors that are advanced (can’t be fully removed or has spread) and are getting worse, where tests show somatostatin receptors. It aims to understand how treatment with lutetium-177 helps people in this situation.
Santiago de Compostela, A CoruñaAges 18–100 - NCT05554003RecruitingPhase 2
Low-grade neuroendocrine tumors: metronomic temozolomide for frail patients
This Phase 2 study tests a gentler, steady schedule of temozolomide in people with advanced low-grade neuroendocrine neoplasms who are “unfit” for stronger treatments. The goal is to shrink or control the cancer while being safer for people with weaker health or organ function.
MilanAges 18 years+ - NCT05237934Recruiting
Study collects tissue samples and tracks neuroendocrine tumors
This study looks at neuroendocrine tumors by collecting tissue (when available) and tracking how the disease behaves over time. It may help researchers better understand these cancers, including rare cases of adrenocortical cancer.
Bethesda, MarylandAges 18–120 - NCT06402695Recruiting
Observational study on digestive and lung NETs
This study follows people with a type of tumor called a neuroendocrine tumor (NET) that started in the digestive system or lungs, to learn more about how the disease progresses and how it responds to treatment.
RomeAges 18 years+ - NCT07536087Recruiting
Heat treatment for pancreatic cysts and neuroendocrine tumors
This trial tests a minimally invasive endoscopic procedure that uses heat to treat certain pancreatic cysts (fluid-filled sacs) and small neuroendocrine tumors (hormone-producing growths). It may be an option if surgery isn't possible or if you prefer to avoid it.
PragueAges 18 years+ - NCT05804331Recruiting
Endoscopy treatment study for large upper stomach/throat lesions
This trial studies a specialized endoscopy procedure to remove larger abnormal growths in the upper digestive tract. It may help people whose lesion size and depth make certain removal techniques a better fit.
Sydney, New South WalesAges 18 years+ - NCT05040360RecruitingPhase 2
Chemotherapy after surgery for high-risk pancreatic NET tumors
This Phase 2 trial studies whether giving chemotherapy after surgery can lower cancer recurrence risk in people with high-risk pancreatic neuroendocrine tumors (NETs). It may help you by testing an added treatment after the tumor has been removed.
Anchorage, AlaskaAges 18 years+ - NCT07728292Recruiting
Underwater removal of small gastric neuroendocrine tumors
This trial tests a special underwater technique to remove small type I gastric neuroendocrine tumors (5-9 mm) during an endoscopy. The goal is to see if it is safe and effective, which could offer a less invasive treatment option.
Hyderabad, TelanganaAges 18–65 - NCT05963867RecruitingPhase 1
First-dose study of a cancer drug taken up by tumors
This Phase 1 study tests how BI 764532 moves into and through tumors in people with small-cell lung cancer or neuroendocrine cancer. It’s likely aimed at understanding the drug’s behavior in your body and tumor, especially if you’ve already tried standard treatments.
AmsterdamAges 18 years+ - NCT06788886Recruiting
Breathing practice for brain and mental health in cancer and other illnesses
This study tests a simple breathing practice to see if it can improve brain health and mental well-being for people with cancer, multiple sclerosis, or their caregivers. You will do light exercises and answer questionnaires, and some participants will also have an MRI brain scan.
Rochester, MinnesotaAges 18–85 - NCT05969860RecruitingPhase 2
Home cancer treatment vs clinic treatment for advanced cancer
This Phase 2 trial compares giving certain standard cancer infusions at home versus in a clinic. It may help people avoid clinic visits while still receiving the same cancer treatment safely.
Jacksonville, FloridaAges 18 years+ - NCT06242119Recruiting
Testing a new PET scanner prototype
This study is testing a new type of PET scanner (called J-PET) to see if it works as well as current PET/CT machines. If you are already scheduled for a whole-body PET/CT scan, participating would mean your scan is done with this experimental scanner instead.
KrakowAges 18 years+ - NCT04429087RecruitingPhase 1
Test of Obrixtamig for DLL3-positive small cell lung tumors
This Phase 1 study tests different doses of obrixtamig in people with small cell lung cancer and other similar neuroendocrine tumors that test positive for a marker called DLL3. It may help doctors understand safety and the best dose, and possibly improve treatment options when standard therapy didn’t work.
Atlanta, GeorgiaAges 18 years+ - NCT06519500Recruiting
Growing tumor models from gastrointestinal neuroendocrine tumor surgery
This study takes tumor tissue from people having surgery for a certain type of gut or pancreas cancer (neuroendocrine tumors). The tissue is used to grow tiny 3D models called organoids in the lab, which can help researchers learn more about the tumor and find better treatments.
RomeAges 18 years+ - NCT07077551RecruitingPhase 2
NALIRIFOX chemo for advanced neuroendocrine cancer after first treatment
This trial tests a combination chemotherapy called NALIRIFOX as a second treatment for people with advanced high-grade neuroendocrine cancers. The goal is to see if it can help when the first treatment didn't work.
Hangzhou, ZhejiangAges 18–75 - NCT04324502Recruiting
Phone app study to collect symptom reports in NET
This study tests a mobile phone app that helps people with neuroendocrine tumors (NETs) report symptoms and quality of life. It may help by making it easier to track how you’re doing during treatment using questionnaires.
LondonAges 18 years+ - NCT04917484RecruitingPhase 2
Higher-precision PRRT dosing versus standard dosing for NEN
This Phase 2 study compares a more personalized (precision) radiation dose plan to the standard dose plan using Lu-177-DOTATOC for people with neuroendocrine neoplasms (NEN) that have worsened or caused major symptoms despite usual treatments. The goal is to see if better planning can improve treatment delivery while staying safe.
Aarhus, Palle Juul-Jensens BoulevardAges 18 years+ - NCT05165407RecruitingPhase 2
Study drugs for advanced high-grade neuroendocrine tumors
This trial tests whether adding three medicines—sintilimab, IBI310, and surufatinib—can control advanced, high-grade neuroendocrine tumors (that cannot be removed by surgery or have spread). It may help if your cancer has grown despite standard treatment, or if you cannot take standard treatment due to side effects.
Beijing, Beijing MunicipalityAges 18–75 - NCT05268783Recruiting
Study of quality of life in people with neuroendocrine tumors
This study asks people with neuroendocrine tumors to report how they’re doing, including quality of life and quality of care. Your answers can help doctors and hospitals understand what support works best.
Brasschaat, AntwerpAges 18 years+
Hear when a new Neuroendocrine Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for neuroendocrine neoplasm?
- Yes. Clin2 currently lists 65 recruiting neuroendocrine neoplasm studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a neuroendocrine neoplasm trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a neuroendocrine neoplasm trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.